CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrog
| Revenue (Most Recent Fiscal Year) | $43.47M |
| Net Income (Most Recent Fiscal Year) | $-17.93M |
| PE Ratio (Current Year Earnings Estimate) | 10.63 |
| PE Ratio (Trailing 12 Months) | 17.24 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 7.95 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.97 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 42.54% |
| Net Margin (Trailing 12 Months) | 42.11% |
| Return on Equity (Trailing 12 Months) | 42.73% |
| Return on Assets (Trailing 12 Months) | 34.19% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.82 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.52 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.68 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.40 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.28 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.30 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.75 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 74.65M |
| Free Float | 70.69M |
| Market Capitalization | $965.21M |
| Average Volume (Last 20 Days) | 3.29M |
| Beta (Past 60 Months) | 1.71 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 34.18% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |